Oncología Médica Traslacional y Terapia Individualizada del Cáncer

de Andrea, CE; Abengozar-Muela, M; Arranz, JA; Climent, MA; Puente, J; Vizcay, A; de la Fuente, LM; Jurado, JM; Bonfill, T; Santander, C; Villa, JC; Pujol, E; Rosero, AC; Gomez, J; Fernández, EM; Fernández, CA; Ramirez, I; Arnáiz, P; López-Janeiro, A; Melero, I; Sanmamed, MF; Pérez-Gracia, JL.

Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients

OncoImmunology. 2025; 14(1): [doi:10.1080/2162402X.2025.2538687]

Radosa, JC; Cobo, SLT; Dzieran, J; Glastetter, E; Chen, C; Lingohr-Smith, M; Pasupuleti, V; Brufsky, A.

Palbociclib treatment in patients with HR+/HER2-advanced or metastatic breast cancer and visceral metastasis: A systematic literature review

BREAST. 2025; 84: [doi:10.1016/j.breast.2025.104569]

Li, J; Deng, T; Gu, YH; Blanco, AC; Li, ZH; Bai, CM; Wu, L; Huang, J; Li, XY; Yao, Y; Song, ZB; Li, YS; Liu, L; Xing, LG; Wu, WM; Martinez-Perez, J; Hubert, A; Zugazagoitia, J; Zhang, J; Wang, YS; Zhao, YQ; Wen, GL; Xia, GH; Zhong, DS; Chen, XQ; Jiang, KR; Wang-Gillam, A; Ding, YL; Liu, SM; Rao, ZY; Liu, XH; Shen, L.

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Cancer Communications. 2025; : [doi:10.1002/cac2.70056]

González-del-Alba, A; Ballesteros, CM; Arranz, JA; Gallardo, E; Sarrió, RG; Campos, FL; Muñoz-Rodríguez, J; Méndez-Vidal, MJ; de Iturriaga, AG.

Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations

Cancers. 2025; 17(19): [doi:10.3390/cancers17193208]

Lonardi, S; Lugowska, I; O'Donnell, A; Jackson, C; Latten-Jansen, LM; North, R; Bahleda, R; Garrido, M; Santoro, A; Chacon, MR; Li, LH; Joseph, D; Vezina, HE; Aras, U; Bennett, B; Perumal, D; Gurm, B; Ng, WT; Harvey, RD; Trigo, J; Calvo, A.

Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study

Journal for ImmunoTherapy of Cancer. 2025; 13(10): [doi:10.1136/jitc-2025-011918]

Cho, BC; Ahn, MJ; Nishio, M; Murakami, H; Wan-Kim, D; Kim, SW; Karam, SD; Estival, A; Lin, CC; Trigo, JM; Alvarez, R; Wang, CL; Xie, MC; Iyer, S; Armstrong, J; Chugh, P; Jiang, HY; Bauman, JE.

Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study

Jto Clinical And Research Reports. 2025; 6(10): [doi:10.1016/j.jtocrr.2025.100884]

Lobato-Delgado, B; Ruiz, M; Font, C; Pachón, V; Castellón, V; Martinez-Marin, V; Salgado, M; Martinez, E; Calzas, J; Ortega, L; Ruperez, A; Pujol, O; Soria, JM; Muñoz, A.

Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study

IJC HEART & VASCULATURE. 2025; 60: [doi:10.1016/j.ijcha.2025.101754]

Soto-Alsar, J; Revuelta-Herrero, JL; Villanueva-Bueno, C; Cobos-Lama, C; Cañete-Muñoz, MA; Muñoz-Martin, A; Garcia-Alfonso, P; Soto-Alvarez, J.

Budget impact analysis of new drugs in oncology and haematology: Principles and practice

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2025; : [doi:10.1002/bcp.70303]

Vaz-Salgado, MA; Valverde-Morales, C; Alvarez, R; Asencio, JM; Collado, E; de Alava, E; Beveridge, RD; Gómez-Mateo, MC; Alegria, IG; Marquina, G; Broto, JM; Martínez-Trufero, J; Narváez, JA; Redondo, A; Sebio, A; Verges, R; Viñals, JM; del Muro, XG.

Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines

Cancers. 2025; 17(19): [doi:10.3390/cancers17193158]

Ramirez, SP; Fidalgo, AP; Ginesta, MPB; Ferre, AD; Madrid, LF; Martinez, AG; Montosa, FG; Madariaga, A; Gómez, TM; Gil-Martin, M.

SEOM-GEICO clinical guidelines on endometrial cancer (2025)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04046-1]

Mezquita, L; Vicente-Herrero, MT; Cruz, P; de la Torre, MVRI; Hidalgo-Coloma, J; Garcia, LC; Gallego, O; Calvo, A; Martinez, K; Perez-Altozano, J; Molina, R; Garcia-Pardo, M; Gutierrez-Sainz, L; Moreno-Atahonero, E; Ore-Arce, M; Serrano, C; Terradillos-Garcia, MJ; Valero, MR; Reinoso-Barbero, L; Rodriguez, CA; Calvo-Cerrada, B.

SEOM-AEEMT consensus on occupational cancer and cancer-associated disability

CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04037-2]

Cánovas, MS; Robles, JL; Verdejo, FJG; Lavin, DC; Olivares, H; Fernández, AG; Salvans, EC; Verduguez, TQ; Coloma, CS; Garay, DF; Cumplido, JD; Pérez, AIF; Bagué, AC; Muñoz, FJT; López, RG; Marin, AM; Martín, AJM.

PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04048-z]

Hoffman-Censits, J; Tsiatas, M; Chang, PMH; Kim, M; Antonuzzo, L; Shin, SJ; Gakis, G; Blais, N; Kim, SH; Smith, A; Arija, JAA; Su, YL; Zagouri, F; Maruzzo, M; Tournigand, C; Forget, F; Schneider, A; Tyroller, K; Jacob, N; Grivas, P; Valderrama, BP.

Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis

ANNALS OF ONCOLOGY. 2025; 36(9): [doi:10.1016/j.annonc.2025.05.010]

Kyriazoglou, A; Zajac, A; Valverde, C; Czarnecka, AM; Blonski, P; Romagosa, C; Seliga, KA; Koulouridi, A; Mala, A; Wagrodzki, M; Silva, TM; Witczak, M; Lugowska, I; Rosinska, M; Alvarez, R; Aguirre, M; Tysarowski, A; Kokkali, S; Georgoulias, V; Serrano, C; Rutkowski, P; Boukovinas, I.

Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe

Esmo Open. 2025; 10(9): [doi:10.1016/j.esmoop.2025.105577]

Blasco, A; López-Tarruella, S; Urruticoechea, A; Carrasco, E; Spera, G; Martin, M; Bermejo, B; Chap, L; Ruiz-Borrego, M; Crown, J; Garcia-Saenz, JA; Chan, A; Guerrero-Zotano, A; Semiglazov, V; Calvo, L; Pienkowski, T; Herranz, J; Slamon, D.

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

ONCOLOGIST. 2025; 30(9): [doi:10.1093/oncolo/oyaf263]

Martelli, V; Vidal, J; Gibert, J; Fernández-Rodriguez, MC; Linares, J; Garcia-Alfonso, P; Páez, D; Alonso, V; Gomez-España, MA; Guix, M; Santos, C; Duran, G; Élez, E; Garcia-Carbonero, R; Ferreiro, R; Pineda, E; Sastre, J; Cano, MT; Manzano, JL; Losa, F; Aranda, E; Rivera, F; Sibilio, A; Toledo, R; Tabernero, J; Salazar, R; Bellosillo, B; Montagut, C.

Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study

Esmo Open. 2025; 10(9): [doi:10.1016/j.esmoop.2025.105760]

Márquez-Rodas, I; Dutriaux, C; Saiag, P; Merino, LD; Alvarez, EC; Robert, C; Rodríguez-Moreno, JF; Arance, A; Cerezuela-Fuentes, P; Montaudié, H; Sanmamed, MF; González-Cao, M; Charles, J; Criado, MPL; Berrocal, A; De Miguel, E; Funck-Brentano, E; Prey, S; de la Gala, MCA; Melero, I; Avilés-Izquierdo, JA; Roman, R; Garcia-Pelaez, B; Rodriguez, S; Trnkova, ZJ; Quintero, M; Maciá, S; Chaney, MF; Dalle, S.

BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203

JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(25): [doi:10.1200/JCO-24-02595]

Pérez-Bilbao, T; López-Tarruella, S; Alonso-Dueñas, M; San Juan, AF; Ferreres-García, K; Martín, M; Peinado, AB; Rojo, F.

Effects of presurgical HIIT in hormone receptor-positive, HER 2-negative breast cancer cases: Two case reports from the GEICAM EFiK study

Physiological Reports. 2025; 13(16): [doi:10.14814/phy2.70511]